Home > Press > IQ Micro Accelerates Product Development Program
Leading Swiss Micro / Nano Technology Centre CSEM Provides Major Support
IQ Micro Accelerates Product Development Program
WEST PALM BEACH, FL | Posted on July 17th, 2007
IQ Micro Inc. (OTCBB: IQMC), exclusive licensor of electro-osmotic membranes and micropumps for the rapidly emerging microfluidic technology sector, announced today that the Swiss Centre for Electronics and Microtechnology, Inc. (CSEM) will play a leading role in IQ Micro's accelerated product development program for the Company's revolutionary micropumps.
IQ Micro Chief Operational Officer Per Arne Lislien said, "Having recently relocated our European operation into CSEM's Central Switzerland Centre in Alpnach, we are working closely in a combined effort to enhance the micropump's design and performance. We have placed top priority on our micropump development program and look forward to continued successes as a result of our CSEM partnership."
CSEM, a private research and development centre that specializes in microtechnology, nanotechnology, microelectronics, systems engineering and communications technologies, will support IQ Micro in its development program of the Company's proprietary micropumps, with a special focus on micro fuel cell applications.
CSEM Chief Operating Officer Philippe Steiert said, "Before contacting CSEM in March 2004, IQ Micro had worked on the theory of the pump's principle and design, and had performed initial testing on the macroscopic scale for verification. CSEM was approached to partner in developing a microfabricated version of the pump and subsequently in preparing the micropump's design and optimization, as well as organizing the microfabrication of the pumps. To achieve these goals, the required innovative methods for the production of these micropumps were jointly developed by IQ Micro and CSEM."
About IQ Micro Inc.
IQ Micro Inc. is an international licensing company that commercializes proprietary technology developed for use in the microfluidics industry, a rapidly emerging industry that has developed from the micro-chip industry. Rather than the traditional flow of electrical current through a silicon chip, microfluidic technology involves circuits of tiny chambers, channels and pumps that direct the flow of liquids on a single micro-chip, as well as membrane technologies.
IQ Micro has been granted exclusive licensing rights to the microfluidics technology developed and patented by the Norwegian company, Osmotex AS. As part of its worldwide licensing agreement, Osmotex's parent company, Osmolife AS, has secured an 85% ownership position in IQ Micro. IQ Micro recently entered into an Agreement in Principle with its parent company, Osmolife AS, to acquire all of the issued and outstanding shares of Lifecare AS, a wholly owned subsidiary of Osmolife AS that is developing advanced micro and nanotechnology for the glucose monitoring market.
IQ Micro is actively pursuing global licensing opportunities for its patented electro-osmotic membrane technology and the "invisible pump," a microfluidic technology with a wide range of consumer, medical and industrial applications.
For more information, visit http://www.iq-micro.com . A profile for investors can be accessed at http://www.hawkassociates.com/iqmcprofile.aspx . An online investor kit, including press releases, current price quotes, stock charts and other valuable information for investors may be found at http://www.hawkassociates.com . To receive free e-mail notification of future releases for IQ Micro, subscribe at http://www.hawkassociates.com/email.aspx .
This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the company's expectations or beliefs concerning future events of the company's financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. The words "may," "could," "should," "believe," "anticipate," "estimate," "expect," "intend," "plan" and similar words are intended to identify forward-looking statements. These factors include the effect of competitive pricing, the company's dependence on the ability of third-party manufacturers to produce components on a basis which is cost-effective to the company, our ability to protect our intellectual property rights from infringement by third parties, our ability to convert our intellectual property rights into product offerings that are accepted by the market, the development of competitors of intellectual property and associated products that are superior to ours or that gain better market acceptance than ours and the ability of our intellectual property rights to keep pace with the advances in technology, market acceptance of the company's products and licensing rights, the effects of government regulation and other factors. Results actually achieved may differ materially from expected results included in these statements. The company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise. Furthermore, this company cautions that the risk factors listed in this paragraph are not exhaustive.
Established in 1984, CSEM (Swiss Centre for Electronics and Microtechnology, Inc.) is a private R&D centre specializing in microtechnology, nanotechnology, microelectronics, systems engineering and communications technologies. CSEM provides its industry customers and partners with tailor-made, innovative product solutions based on its commercial and technological expertise, further expanded by the results of its applied research. Additionally, through the establishment of start-up businesses, it actively contributes to developing Switzerland as a centre of industry and commerce. To date, CSEM has established a total of 23 new enterprises with more than 500 employees. More than 300 highly qualified CSEM employees from varied scientific and technical fields work in Neuchâtel, Zurich and Alpnach. They represent more than 20 different nationalities and constitute the basis of the company's creativity, dynamism and innovation potential. Further information is available at http://www.csem.ch .
For more information, please click here
D.P. Martin & Associates
Investor Relations for IQ Micro
Copyright © Market Wire
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Switching to spintronics: Berkeley Lab reports on electric field switching of ferromagnetism at room temp December 17th, 2014
ORNL microscopy pencils patterns in polymers at the nanoscale December 17th, 2014
Unraveling the light of fireflies December 17th, 2014
First Home-Made Edible Herbal Nanodrug Presented to Pharmacies across Iran December 17th, 2014
Chemists Fabricate Novel Rewritable Paper: An attractive alternate to regular paper, UC Riverside-developed technology helps address increasing problems in environment and resource sustainability December 2nd, 2014
Dicerna Announces License Agreement with Tekmira to Advance Dicerna’s PH1 Development Program November 17th, 2014
First genetic-based tool to detect circulating cancer cells in blood: NanoFlares light up individual cells if breast cancer biomarker is present November 17th, 2014
Ki-Bum Lee Patents Technology To Advance Stem Cell Therapeutics November 13th, 2014